“The need to consider the wider agenda in systematic reviews and meta-analysis: breadth, timing, and depth of the evidence.”
Ioannidis and colleague are at it once again, looking at the quality of evidence that gives rise to the approval and eventual widespread use of clinical pharmaceuticals. In this case, they show that a common cancer drug is substantially less effective that is assumed by existing meta-analysis, the evidence used to approve the drug, and probably the doctors using the drug on a day-to-day basis. Drug companies dominate evidence and this can only be a bad thing for safety and efficacy.
Click the title to see the article.